AnaptysBio, Inc.
ANAB
$20.55
$1.497.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.11M | 30.02M | 10.97M | 7.18M | 9.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.11M | 30.02M | 10.97M | 7.18M | 9.01M |
| Cost of Revenue | 42.59M | 42.21M | 42.00M | 37.04M | 33.53M |
| Gross Profit | 524.00K | -12.20M | -31.03M | -29.86M | -24.52M |
| SG&A Expenses | 10.19M | 10.56M | 9.30M | 12.34M | 10.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.78M | 52.77M | 51.29M | 49.38M | 43.80M |
| Operating Income | -9.67M | -22.76M | -40.32M | -42.20M | -34.80M |
| Income Before Tax | -21.79M | -32.85M | -46.65M | -43.94M | -42.22M |
| Income Tax Expenses | -6.00K | -- | 9.00K | -- | -4.00K |
| Earnings from Continuing Operations | -21.78M | -32.85M | -46.66M | -43.94M | -42.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.78M | -32.85M | -46.66M | -43.94M | -42.21M |
| EBIT | -9.67M | -22.76M | -40.32M | -42.20M | -34.80M |
| EBITDA | -9.53M | -22.61M | -40.17M | -42.04M | -34.63M |
| EPS Basic | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 |
| Normalized Basic EPS | -0.45 | -0.71 | -1.07 | -1.02 | -0.82 |
| EPS Diluted | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 |
| Normalized Diluted EPS | -0.45 | -0.71 | -1.07 | -1.02 | -0.82 |
| Average Basic Shares Outstanding | 30.45M | 28.89M | 27.36M | 26.80M | 26.59M |
| Average Diluted Shares Outstanding | 30.45M | 28.89M | 27.36M | 26.80M | 26.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |